AKT1 and lung carcinoma: Surprisingly, after 72 h treatment, combined treatment caused a complete inhibition of AKT phosphorylation in lung cancer cells, whereas treatment with either abemaciclib or gilteritinib showed no obvious effect on AKT pathway (Figure 3A).